OakChart

Cocrystal Pharma Inc

COCPHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 11:15 AM ET

1.02-0.01 (-0.97%)
2026-11-11 17:16 CET
Market cap
19.84 USD m
Revenue, TTM
0.33 USD m
Net income, TTM
-9.94 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-0.76
P/E
-
Compare

Price

COCP against its 20, 50 and 200-day averages
2050200miss
0.801.001.201.40209K418KMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26COCPclose 1.0220-day 1.0050-day 1.09200-day 1.101.0252w low

49.8% under the 52-week high of 2.03 on 2 Apr 2026. 52-week low 0.76 on 29 Jul 2026. Last 15 sessions, 25.0% high to low

Profile

COCP
52-week range, 20% of the way up
0.762.03

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses. Cocrystal employs unique structure-based technologies to create first- and best-in-class antiviral drugs. The company was founded in 2008 and is headquartered in Bothell, WA.

Employees10
IPOApr 01, 2008
Beta1.60
ATR, 14d0.07
Rel volume0.78
Short float1.42%
Insider own33.53%
Inst own5.97%

Snapshot

6 groups

Valuation

Index-
Market Cap19.65M
Enterprise Value18.75M
Income-9.94M
Sales0.33M
Book/sh0.08
Cash/sh0.12
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees10
IPOApr 01, 2008

Ratios

P/E-
Forward P/E-
PEG-
P/S59.54
P/B13.47
P/C8.77
P/FCF-
EV/EBITDA-
EV/Sales56.81
Quick Ratio1.24
Current Ratio1.24
Debt/Eq1.29
LT Debt/Eq0.95
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.76
EPS next Y-0.47
EPS next Q-0.18
EPS this Y7.05%
EPS next Y34.48%
EPS next 5Y6.87%
EPS past 3/5Y45.26% 17.90%
Sales past 3/5Y- -
EPS Y/Y TTM38.55%
Sales Y/Y TTM-
EPS Q/Q-13.61%
Sales Q/Q-
EarningsAug 17
EPS/Sales Surpr.-39.39% -

Ownership

Insider Own33.53%
Insider Trans1.33%
Inst Own5.97%
Inst Trans15.22%
ROA-151.10%
ROE-311.68%
ROIC-488.83%
Gross Margin37.27%
Oper. Margin-3063.64%
Profit Margin-3011.52%
SMA202.01%
SMA50-6.19%
SMA200-7.37%
Trades-

Technical

Shs Outstand13.79M
Shs Float12.81M
Short Float1.42%
Short Ratio3.89
Short Interest0.18M
52W High2.03 -49.75%
52W Low0.76 34.21%
Volatility8.62% 7.25%
ATR (14)0.07
RSI (14)48.03
Beta1.60
Rel Volume0.78
Avg Volume46.60K
Volume11,167

Performance

Perf Week0.99%
Perf Month-5.56%
Perf Quarter-7.27%
Perf Half Y-20.31%
Perf YTD4.19%
Perf Year-9.73%
Perf 3Y-46.32%
Perf 5Y-90.86%
Perf 10Y-99.42%
Recom1.00
Target Price7.00
Prev Close1.03
Price1.02
Change %-0.97%

Analyst ratings

latest 1 of 1
DateActionAnalystRating changeTargetImplied
Jul 08, 2020InitiatedHH.C. WainwrightBuy$5+390.2%

Peers

Mkt cap
TickerCompanyMkt cap
AVIRAtea Pharmaceuticals Inc336.48M
ENTAEnanta Pharmaceuticals Inc336.26M
TRAWTraws Pharma Inc3.71M
ALGSAligos Therapeutics Inc16.67M
NNVCNanoViricides Inc36.63M
ASMBAssembly Biosciences Inc454.45M
ABUSArbutus Biopharma Corp757.75M
IVVDInvivyd Inc177.00M
ACXPAcurx Pharmaceuticals Inc5.90M
SNGXSoligenix Inc7.56M

Insider trading

10 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
FROST PHILLIP MD ET ALDirectorAug 05 '26Buy0.9810,0009,8161,993,551Aug 06 05:11 PM
FROST PHILLIP MD ET ALDirectorAug 03 '26Buy0.9475,00070,5901,983,551Aug 05 04:10 PM
FROST PHILLIP MD ET ALDirectorFeb 24 '26Buy1.0020,00019,9521,908,551Feb 25 04:10 PM
FROST PHILLIP MD ET ALDirectorFeb 06 '26Buy0.9550,00047,2801,888,551Feb 09 04:10 PM
FROST PHILLIP MD ET ALDirectorDec 31 '25Buy0.9550,00047,2751,838,551Jan 02 04:10 PM
FROST PHILLIP MD ET ALDirectorDec 30 '25Buy0.9720,00019,3101,788,551Dec 31 04:10 PM
FROST PHILLIP MD ET ALDirectorDec 26 '25Buy0.9740,00038,9441,768,551Dec 29 09:24 AM
FROST PHILLIP MD ET ALDirectorDec 24 '25Buy0.9725,00024,2581,728,551Dec 29 09:24 AM
FROST PHILLIP MD ET ALDirectorNov 26 '25Buy0.994,0003,9751,703,551Nov 28 09:00 AM
FROST PHILLIP MD ET ALDirectorNov 25 '25Buy0.9420,00018,8121,699,551Nov 25 08:17 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 206
  • A norovirus breakthrough?; another womens healthtech haul (Pharma Voice) +6.14%
  • Cocrystal Pharmas new CEO hopes to crack the norovirus code (Pharma Voice)
  • Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment (GlobeNewswire) +5.08%
  • Cocrystal Pharma: The Strategic Reset Investors May Be Missing (Exec Edge) +5.45%
  • Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors (GlobeNewswire)
  • Loading…
  • Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health (GlobeNewswire) +14.63%
  • Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer (GlobeNewswire)
  • Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza (GlobeNewswire)
  • Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results (GlobeNewswire)
  • Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection (GlobeNewswire)
  • BC-Most Active Stocks (Associated Press) +48.04%
  • Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive (GlobeNewswire)
  • Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-17-0.230-0.165-0.2300.100.002
2026Q12026-05-15-0.170-0.150-0.1700.100.002
2025Q42026-03-31-0.160-0.175-0.1760.000.002
2025Q32025-11-14-0.190-0.215-0.1860.000.002
2025Q22025-08-14-0.200-0.230-0.2020.000.002
2025Q12025-05-15-0.230-0.505-0.2260.000.002
2024Q42025-03-31-0.310-0.530-0.3210.000.003
2024Q32024-11-13-0.490-0.570-0.4850.000.003
2024Q22024-08-14-0.530-0.477-0.5250.000.003
2024Q12024-05-13-0.390-0.540-0.3890.000.002
2023Q42024-03-29-0.320-0.597-0.4390.000.003
2023Q32023-11-13-0.410-0.530-0.4100.000.003
2023Q22023-08-14-0.500-0.580-0.4140.000.273
2023Q12023-05-15-0.640-0.600-0.6370.000.173
2022Q42023-03-29-0.590-0.727-0.5530.000.003
2022Q32022-11-14-0.700-0.487-8.4000.000.083

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2018FY-21.000--1.751--
2019FY-17.640-3.360-1.5126.60-
2020FY-2.040-2.400-2.0972.012.00
2021FY-1.920-1.920-1.9260.000.00
2022FY-4.770-4.100-4.7690.000.00
2023FY-1.870-2.093-1.8630.000.00
2024FY-1.720-1.930-1.7210.000.00
2025FY-0.780-0.795-0.7800.000.00
2026FY--0.725--0.17
2027FY--0.475--0.00
2028FY--0.630--0.00

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-082000.000.000.00
2026Q3S2026-09-031000.000.000.00
2026Q3S2026-08-172000.000.000.00
2026Q3S2026-05-152000.000.000.00
2026Q3S2026-04-072000.000.000.00
2026Q3S2026-03-311000.000.000.00
2026Q3S2025-11-141000.000.000.00
2026Q3S2025-11-111000.000.000.00
2026Q3S2025-11-101000.000.000.00
2026Q3S2025-11-091000.000.000.00
2026Q3S2025-11-081000.000.000.00
2026Q3S2025-11-071000.000.000.00
2026Q3S2025-11-061000.000.000.00
2026Q3S2025-11-051000.000.000.00

Estimate history

EPS, annual-0.03-1.751-1.512-2.097-1.926-4.769-1.863-1.721-0.782-0.7587
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.525-0.485-0.321-0.226-0.202-0.186-0.176-0.167-0.23
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual006.5642.014000000.33
Period201720182019202020212022202320242025TTM
Sales, quarterly00000000.2250.105
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual24.27729.93835.155.878.1228.14310.17410.17413.78413.789
Period201720182019202020212022202320242025MRQ
Shares, quarterly10.17410.17410.17410.17410.17413.04113.78413.78713.789
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.330.000.000.000.000.002.016.560.00
Cost of Goods Sold Incl. D&A0.210.380.13-1.390.390.38--0.05
Gross Profit0.12-0.38-0.131.39-0.39-0.38---0.05
Selling, General and Administrative Excl. Other10.238.6417.7522.5517.7513.8411.268.618.97
Research and Development6.095.0612.5415.1712.398.415.973.754.62
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-10.11-9.02-17.88-21.16-18.14-14.22-9.59-2.30-9.02
Interest Expense0.000.000.00-0.000.000.010.020.06
Unusual Expense0.000.000.00-2.6020.68-0.050.0545.8553.49
Net Income Before Taxes-9.94-8.83-17.50-17.98-38.84-14.19-9.65-48.17-62.63
Income Taxes0.000.000.000.000.000.000.000.00-13.58
Consolidated Net Income-9.94-8.83-17.50-17.98-38.84-14.19-9.65-48.17-49.05
Net Income From Continuing Operations-9.94-8.83-17.50-17.98-38.84-14.19-9.65-48.17-49.05
Net Income-9.94-8.83-17.50-17.98-38.84-14.19-9.65-48.17-49.05
EPS (Recurring)-0.72-0.78-1.72-2.05-2.99-1.93-2.09-0.50-0.41
EPS (Basic, Before Extraordinaries)-0.76-0.78-1.72-1.86-4.77-1.93-2.10-1.51-1.75
EPS (Diluted)-0.76-0.78-1.72-1.86-4.77-1.93-2.10-1.51-1.75
EBITDA-9.90-8.64-17.75-22.55-17.75-13.84-9.25-2.05-8.97
Non-Operating Income (Expense)0.170.190.370.58-0.02-0.010.000.00-0.06
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.280.270.640.800.860.720.660.350.39
Price To Sales Ratio43.87-----37.2928.86-
Gross Margin37.27--------
Operating Margin-3,063.64------475.97-35.09-
Net Margin-3,011.52------479.05-733.84-
Shares Outstanding13.7913.7810.1710.178.148.125.8735.1529.94
Market Capitalization19.8419.8420.5517.5215.8863.3595.8017.42107.78

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.100.230.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.010.090.090.010.020.030.030.03
Gross Profit0.090.13-0.09-0.01-0.02-0.03-0.03-0.03
Selling, General and Administrative Excl. Other3.282.492.392.082.092.323.205.01
Research and Development2.141.371.620.951.121.362.043.24
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-3.18-2.36-2.48-2.09-2.11-2.34-3.23-5.04
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-3.16-2.30-2.43-2.05-2.06-2.30-3.27-4.94
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-3.16-2.30-2.43-2.05-2.06-2.30-3.27-4.94
Net Income From Continuing Operations-3.16-2.30-2.43-2.05-2.06-2.30-3.27-4.94
Net Income-3.16-2.30-2.43-2.05-2.06-2.30-3.27-4.94
EPS (Recurring)-0.23-0.17-0.18-0.19-0.20-0.23-0.32-0.49
EPS (Basic, Before Extraordinaries)-0.23-0.17-0.18-0.19-0.20-0.23-0.32-0.49
EPS (Diluted)-0.23-0.17-0.18-0.19-0.20-0.23-0.32-0.49
EBITDA-3.17-2.27-2.39-2.08-2.09-2.32-3.20-5.01
Non-Operating Income (Expense)0.020.060.060.040.050.04-0.040.10
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.090.080.060.050.080.080.090.25
Price To Sales Ratio43.8761.88------
Gross Margin88.5759.56------
Operating Margin-3,032.38-1,047.11------
Net Margin-3,013.33-1,021.78------
Shares Outstanding13.7913.7913.7813.0410.1710.1710.1710.17
Market Capitalization19.8413.9213.4916.3015.1614.4520.5517.91

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments7.109.9426.4337.2258.7633.067.472.750.78
Short Term Receivables0.711.220.890.720.000.560.640.001.29
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.330.431.772.240.570.400.170.190.10
Total Current Assets8.1311.5829.0940.1859.3234.028.282.942.18
Net Property, Plant & Equipment1.481.852.120.620.931.091.110.380.12
Total Investments and Advances0.000.000.000.000.000.000.000.000.03
Intangible Assets0.000.000.000.0019.0919.0919.0965.19119.10
Deferred Tax Assets-------19.780.29
Other Assets0.100.030.050.050.050.050.050.040.00
Total Assets9.7113.4631.2640.8479.3954.2428.5388.34121.72
Short Term Debt Incl. Current Port. of LT Debt0.330.300.240.240.240.220.280.210.00
Accounts Payable0.891.541.220.610.580.661.510.000.84
Other Current Liabilities0.990.581.800.360.730.480.491.340.57
Total Current Liabilities2.212.433.261.221.541.362.291.561.41
Long Term Debt1.171.501.610.060.300.380.540.121.01
Provision for Risks Charges0.000.000.000.000.000.000.000.00-
Deferred Tax Liabilities-------19.7813.88
Other Liabilities0.000.000.000.000.000.000.000.000.03
Total Liabilities3.383.934.881.271.841.742.8221.4516.32
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity6.339.5226.3839.5777.5552.5125.7166.89105.40
Total Shareholders Equity6.339.5226.3839.5777.5552.5125.7166.89105.40
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity6.339.5226.3839.5777.5552.5125.7166.89105.40
Total Liabilities & Stockholders Equity9.7113.4631.2640.8479.3954.2428.5388.34121.72
Book Value Per Share0.460.942.594.869.558.940.732.234.34
Tangible Book Value Per Share0.460.942.594.867.205.690.190.06-0.56
Full-Time Employees101112121313111010
Price to Book Ratio13.601.620.570.030.821.820.681.611.46
Return on Assets-76.23-78.29-49.89-64.60-21.23-23.31-82.43-46.70-0.45
Return on Equity-111.40-97.50-54.54-66.32-21.81-24.67-104.04-56.94-0.59
Return on Invested Capital-117.72-158.72-64.24-98.01-18.22-18.24-183.54-73.20-0.58
Quick Ratio3.684.778.9233.0438.4025.053.621.891.55
Current Ratio3.684.778.9233.0438.4025.053.621.891.55

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-10.30-8.83-17.50-17.98-38.84-14.19-9.65-48.17-49.05
Depreciation0.370.380.13-1.390.390.380.340.250.05
Other Funds (Non Cash)-0.03-0.030.752.3619.730.480.5446.0754.17
Funds from Operations-9.95-8.49-16.63-17.01-18.72-13.32-8.77-1.85-8.41
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital1.690.290.142.34-2.710.60-1.060.290.12
Cash from Operating Activities-8.26-8.19-16.49-14.67-21.44-12.72-9.83-1.56-8.29
Capital Expenditures0.00-0.01-0.01-0.12-0.07-0.05-0.24-0.15-0.03
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.001.40
Cash from Investing Activities-0.01-0.01-0.01-0.12-0.07-0.05-0.24-0.151.37
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock5.635.370.004.000.0038.5135.786.647.91
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock5.635.370.004.000.0038.5135.786.647.91
Proceedsfrom Stock Options0.160.150.004.000.0038.5135.786.647.68
Issuance or Reduction of Debt, Net0.000.000.00-0.01-0.03-0.04-0.12-0.210.98
Change in Long Term Debt0.000.000.00-0.01-0.03-0.04-0.12-0.210.98
Issuance of Long Term Debt0.000.000.000.000.000.000.000.001.00
Reduction of Long Term Debt0.000.000.00-0.01-0.03-0.04-0.12-0.21-0.02
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities5.635.370.003.99-0.0338.4735.666.428.89
Net Change in Cash-2.64-2.84-16.49-10.79-21.5425.7025.594.721.98
Free Cash Flow--8.20-16.49-14.78-21.51-12.77-10.07-1.71-8.32
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00-13.58

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments2.244.767.107.804.847.00
Short Term Receivables0.740.760.710.511.641.45
Inventories0.000.000.000.000.000.00
Other Current Assets0.260.420.330.470.280.39
Total Current Assets3.245.948.138.786.768.83
Net Property, Plant & Equipment1.301.391.481.571.651.75
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.110.100.100.090.090.09
Total Assets4.657.439.7110.458.5110.66
Short Term Debt Incl. Current Port. of LT Debt0.350.340.330.330.320.31
Accounts Payable1.891.370.890.740.860.81
Other Current Liabilities0.370.520.990.450.660.81
Total Current Liabilities2.622.232.211.521.831.93
Long Term Debt0.991.081.171.261.341.42
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities3.603.313.382.783.173.35
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity1.044.126.337.675.337.30
Total Shareholders Equity1.044.126.337.675.337.30
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity1.044.126.337.675.337.30
Total Liabilities & Stockholders Equity4.657.439.7110.458.5110.66
Book Value Per Share0.080.300.460.590.520.72
Tangible Book Value Per Share0.080.300.460.590.520.72
Full-Time Employees--10---
Price to Book Ratio13.602.201.662.382.081.52
Return on Assets-151.10-97.64-76.23-72.50-83.52-85.20
Return on Equity-311.68-154.62-111.40-94.94-110.56-106.05
Return on Invested Capital-155.63-44.24-32.34-22.96-30.79-26.36
Quick Ratio1.242.663.685.783.694.57
Current Ratio1.242.663.685.783.694.57

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-3.19-2.30-2.56-2.25-2.15-2.30
Depreciation-0.070.090.100.250.020.02
Other Funds (Non Cash)0.090.08-0.02-0.180.090.08
Funds from Operations-3.16-2.12-2.49-2.18-2.04-2.19
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.62-0.220.650.63-0.23-0.75
Cash from Operating Activities-2.54-2.34-1.84-1.55-2.27-2.94
Capital Expenditures0.000.00-0.00-0.010.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.00-0.00-0.010.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.001.094.540.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.001.094.540.000.00
Proceedsfrom Stock Options0.000.00-4.384.540.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.000.001.094.540.000.00
Net Change in Cash-2.54-2.34-0.742.98-2.27-2.94
Free Cash Flow---1.84-1.56-2.27-2.94

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.42%0.2M12.8M57.63K
2026-10-151.40%0.2M12.8M56.03K
2026-09-301.37%0.2M12.8M54.75K
2026-09-152.52%0.3M12.8M60.66K
2026-08-312.52%0.3M12.8M70.68K
2026-08-143.00%0.3M10.2M81.46K
2026-07-313.78%0.4M10.3M86.29K
2026-07-153.85%0.4M10.3M115.94K
2026-06-303.94%0.4M10.3M2.43M
2026-06-154.53%0.4M9.1M2.39M
2026-05-291.58%0.1M9.1M2.41M
2026-05-152.13%0.2M9.1M2.40M
2026-04-306.47%0.6M9.1M2.43M
2026-04-1510.91%1.0M9.1M2.44M
2026-03-311.64%0.1M9.1M62.92K
2026-03-132.36%0.2M9.1M70.39K
2026-02-272.91%0.3M9.1M71.95K
2026-02-132.60%0.2M9.1M75.56K
2026-01-302.21%0.2M9.1M77.11K
2026-01-151.76%0.2M9.1M110.84K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-06SCHEDULE 13D/ASEC
2026-09-098-KCurrent report2026-09-09SEC
2026-08-213Initial statement of beneficial ownership of securities2026-08-12SEC
2026-08-188-KCurrent report2026-08-12SEC
2026-08-178-KCurrent report2026-08-17SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-07SCHEDULE 13D/ASEC
2026-08-07SCHEDULE 13DSEC
2026-08-064Statement of changes in beneficial ownership of securities2026-08-05SEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-038-KCurrent report2026-07-31SEC
2026-07-178-KCurrent report2026-07-14SEC
2026-06-098-KCurrent report2026-06-03SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-033Initial statement of beneficial ownership of securities2026-06-03SEC
2026-06-038-KCurrent report2026-06-03SEC
2026-05-27DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-05-27DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-05-27SEC
2026-05-268-KCurrent report2026-05-26SEC
2026-05-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-01EFFECTEffectiveness filing by commission orderSEC
2026-04-308-KCurrent report2026-04-30SEC
2026-04-29CORRESPSEC
2026-04-28UPLOADUpload SubmissionSEC
2026-04-23S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-04-028-KCurrent report2026-04-02SEC
2026-03-3110-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-318-KCurrent report2026-03-31SEC
2026-03-138-KCurrent report2026-03-10SEC
2026-03-098-KCurrent report2026-03-09SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-0880.41K200
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-0267.23K200
2026-010000
2025-12129.79K400
2025-1122.79K200

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC2.60%
RENAISSANCE TECHNOLOGIES LLC1.30%
TWO SIGMA INVESTMENTS, LP1.27%
GEODE CAPITAL MANAGEMENT, LLC0.65%
BlackRock, Inc.0.53%
CITADEL ADVISORS LLC0.33%
Neuberger Berman Group LLC0.23%
XTX Topco Ltd0.21%
JANE STREET GROUP, LLC0.19%
VANGUARD FIDUCIARY TRUST CO0.17%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND1.36%
VANGUARD EXTENDED MARKET INDEX FUND1.24%
Fidelity Extended Market Index Fund0.26%
Fidelity Series Total Market Index Fund0.05%
Fidelity Total Market Index Fund0.04%
Fidelity Nasdaq Composite Index Fund0.01%

OakChart. COCP. Cached 15 minutes.